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after primary treatment. METHODS: Data derive from the
ﬁnancial database of the National Health Insurance Fund
Administration (OEP) and based on the S7200 ICD code and
Diagnosis Related Groups 371A,B,C,H,K 374A,B,C and
375A,B,C. Patients with polytrauma or severe comorbidities
were excluded from the study. Our retrospective analysis
includes patients with femoral neck fracture identiﬁed with
Social Security Identiﬁcation number (TAJ) and discharged in
2000. We calculated the cost of acute and chronic hospital care,
outpatient care and sick-pay. The following exchange rate 
was used: 1 Euro (EUR) = 253,23 Hungarian Forint (HUF).
RESULTS: Altogether 518 patients were included into the study.
The average cost per patient (for both with and without com-
plications) was as follow. Acute inpatient care: arthroplasty 1357
EUR, screw ﬁxation 1033EUR, DHS: 925EUR. Chronic inpa-
tient care: arthroplasty 24EUR, screw ﬁxation 75EUR, DHS: 52
EUR. Sick-pay: arthroplasty 896EUR, screw ﬁxation 994EUR,
DHS: 914EUR. Outpatient care: arthroplasty 21EUR, screw ﬁx-
ation 51EUR, DHS: 39EUR. Total health insurance expendi-
tures were: arthroplasty 2299EUR, screw ﬁxation 2153EUR,
DHS: 1930EUR. Total health insurance expenditures per patient
with complications were: arthroplasty 3063EUR, screw ﬁxation
3971EUR, DHS: 2481EUR. Total health insurance expenditures
per patient without complications were: arthroplasty 2215EUR,
screw ﬁxation 1743EUR, DHS: 1813EUR. The rate of further
treatment was arthroplasty 8.3%, screw ﬁxation 18.4%, DHS:
14.7%. CONCLUSIONS: We found the highest cost in patients
with complications in screw ﬁxation, while patients without
complications in arthroplasty. In both cases (with and without
complications) dynamic hip screw had the lowest cost.
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OBJECTIVES: We determined the cost-effectiveness of monthly
ibandronate compared to weekly bisphosphonate (BP) treat-
ments for women in the US, age ≥50 years, with prevalent radi-
ologic vertebral deformity and hip BMD T-score ≤-2.5.
METHODS: A Markov model was developed to evaluate the
lifetime cost-effectiveness of monthly ibandronate and weekly
BPs. Vertebral, hip, and wrist fracture efﬁcacy were assigned a
bisphosphonate class effect as estimated by the literature. Per-
sistence with weekly BPs was evaluated at rates reported from
observational studies (36% at year 1, 24% for years 2 through
5). Fifty-percent relative improvement in persistence (54% at
year 1, 36% for years 2 through 5) among women receiving
ibandronate was assumed based on previous improvements in
persistence for weekly BPs. Both fracture risk and mortality were
allowed to increase as patients aged. Yearly drug costs were ref-
erenced to wholesale acquisition costs for each BP. Direct health
resource costs for fracture states were estimated from published
literature and discounted 3% per annum. All costs were reported
in 2004 US$. RESULTS: More fractures were avoided (vs. no
treatment) with monthly ibandronate (94.13 per 1000 women)
than with weekly BPs (57.57 per 1000 women), resulting in low
lifetime fracture care costs/woman ($6726 and $6918, respec-
tively). Five-year drug costs/patient were $1138 with weekly BPs
and $1576 under conditions of improved persistence with
monthly ibandronate. The incremental cost per quality-adjusted
life year gained (vs. no treatment) was lower with monthly iban-
dronate ($26,725) compared to weekly BPs ($31,601). Chang-
ing assumptions in the model to that of previously published
cost-effectiveness models produced similar results, providing
external validity for this model. CONCLUSION: Ibandronate is
a cost-effective intervention for the treatment of postmenopausal
osteoporosis. Incremental persistence with BP therapy thus
improves the beneﬁt realized in patient populations. These ben-
eﬁts include fewer fractures for patients without signiﬁcant
increases in costs to payers.
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OBJECTIVE: To estimate the cost of falls in LTCFs.
METHODS: The study employed a non-randomized, before and
after comparison with control group design. A multi-facility
long-term care company provided data from residents institu-
tionalized between January 1, 2002 and October 30, 2004. Data
included Minimum Data Set (MDS) observations, Resource Uti-
lization Group (RUG) classiﬁcations, and demographics. An
index date was assigned to each resident to identify pre-and post-
periods. The index date was deﬁned as the date of the ﬁrst fall
for fallers and as the date of the ﬁfth MDS measurement for non-
fallers. Direct medical cost estimates were based on MDS mea-
sures of hospital, emergency room, and physician utilization and
on average Medicare reimbursement rates. Costs related to
changes in resident functioning were estimated from RUG
payment rates. Total reimbursement per resident per day (PRPD)
was calculated as the sum of RUG and medical service reim-
bursements. Fall-related costs were estimated by comparing
between-group differences in pre- to post-index period changes
in reimbursement. Regression analysis was used to control for
between-group differences. The dependent variable was the
natural log of post-period total reimbursement. Independent
variables included group, pre-period reimbursement, post-period
length of stay, age, gender, race, and severity of illness as mea-
sured by a modiﬁed Charlson Comorbidity Index. RESULTS:
The sample included 1298 fallers and 1509 non-fallers. Fallers
had substantially more fractures and higher medical services uti-
lization in the post-period than non-fallers. Total reimbursement
for fallers decreased from $107 to $37 PRPD compared to a
decrease from $98 to $24 for non-fallers. Regression analysis
indicated that reimbursement in the post-period was 40% higher
for fallers than non-fallers after controlling for demographic and
disease differences and pre-period reimbursement. CONCLU-
SION: Falls in LTCFs result in substantial costs, primarily due
to higher hospitalization rates.
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OBJECTIVES: The aim of the study is to analyze on a 3 years
follow up the 50–100% impaired ability to work related to
medial fracture of femoral neck of patients in active age group
regarding the surgical methods, the progressivity level of the
primary treatment, rehabilitation care, age group and residence
of patients, and the possible complications. METHODS: Data
derive from the database of the National Health Insurance Fund
Administration and based on the ICD-10 code S7200 (femoral
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neck fracture) and the Hungarian Diagnosis Related Groups.
Patients with polytrauma or severe comorbidities were excluded.
Our retrospective analysis includes patients under 60 with
femoral neck fracture identiﬁed with Social Security Identiﬁca-
tion number (TAJ) and discharged in 2000. RESULTS: A total
of 518 patients met the selection criteria and 23.7% of them (N
= 123) had impaired ability to work. The proportion of patients
with impaired ability to work was 41.3% in patients with further
treatment, 50% in patients with secondary prosthesis and 20%
in patients with one deﬁnitive treatment. The proportion of
patients with impaired ability to work according to the method
of primary surgery was 27.1% in arthroplasty, 23.7 in screw ﬁx-
ation and 20.6% in DHS. A total of 16.3% of disabled patients
received rehabilitation treatment. The proportion of disabled
patients increased in higher age groups. We found higher than
national average disability ratio in regions with higher unem-
ployment rate and lower employment rate. CONCLUSIONS:
We found higher impaired ability to work ratio in patients with
complications receiving further treatment and in arthroplasty. In
order to reduce the impaired ability to work, the sick-pay period
should be used more efﬁciently. The frequency of impaired ability
to work is not only a health related problem but it is an effect
of social and economic processes.
OSTEOPOROSIS—Health Care Use & Policy Studies
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OBJECTIVES: Approximately eight million women and two
million men in the U.S. suffer from osteoporosis, a disease that
causes over 1.5 million fractures each year. The cost to Medic-
aid for anti-osteoporosis medications topped $85 million in the
ﬁrst quarter of 2004. The objective of this study is to analyze
price, cost, utilization, and market shares of oral anti-osteo-
porosis medications in U.S. Medicaid programs, with the speciﬁc
purpose of assessing interbrand competition in a tightly oligop-
olistic market. METHODS: There are ﬁve oral medications for
osteoporosis, including Didronel® (etidronate), Skelid® (tilu-
dronate), Actonel® (risedronate), Fosamax® (alendronate), and
Evista® (raloxifene). Data from the First DataBank® were used
to calculate the monthly Average Wholesale Price (AWP) per
daily dose for each drug over the period 1990–2004. Data from
the National Medicaid Pharmacy claims were used to calculate
quarterly drug prescriptions, market shares, and reimbursements
over essentially the same time period. RESULTS: The three most
frequently prescribed drugs are alendronate (utilization reached
600,000 scripts in the 1st quarter 2004); risedronate whose use
increased from 90 scripts in the 2nd quarter 1999 to 400,000 in
the 1st quarter 2004; and raloxifene with utilization of 190,000
scripts in the 1st quarter 2004. Each of these drugs has an AWP
per daily dose in the $2.00 to $4.00 range. Interestingly, the
Medicaid cost per prescription for risedronate decreased from
$300 in 1999 to $80 in 2004. Though not widely prescribed, the
AWP for tiludronate is much higher than for its competitors at
$15.00 per daily dose. CONCLUSIONS: There is no indication
that market shares or prices of branded medications are respond-
ing to new entry in the anti-osteoporosis drug market. Move-
ment in prices and utilization are driven much more by dosage
and compliance issues.
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OBJECTIVE: To examine the trend in clinical management of
patients with fragile fractures before and after the implementa-
tion of the Health Plan Employer Data and Information Set
(HEDIS) osteoporosis measure. METHODS: Two cohorts of
Medicare Beneﬁciaries with continuous enrollment for at least
18 months and a fracture during the measurement year and no
use of osteoporosis medication or BMD screening in the pre-
ceding 12 months were identiﬁed in the MarketScan Medicare
Supplemental and COB database for the measurement years
2000–2005. Per HEDIS, each measurement year began on July
1st of the preceding year and continues through June 30th of the
measurement year. The ﬁrst cohort consisted of women aged 67
and older, while the second cohort consisted of men and women
aged 65 and older. Fractures were identiﬁed according to HEDIS
deﬁnitions. Clinical management was assessed by the presence of
a claim for BMD screening and/or a prescription for a bisphos-
phonate or other osteoporosis-speciﬁc medication in the year fol-
lowing the fracture. Adjusted rates of change in screening and
treatment were estimated using multivariate logistic regression.
RESULTS: In the measurement year 2000, 8.4% of Cohort 1
underwent BMD screening and 11.2% received pharmacologi-
cal treatment. For Cohort 2, the rates were 6.5% and 8.3%,
respectively. By 2005, BMD screening had increased by 21% and
treatment increased by 15% for Cohort 1. For Cohort 2, the
rates increased by 42% and 22%, respectively. After adjusting
for patient age, sex, fracture location, provider specialty, geo-
graphic region and capitated versus non-capitated health plan,
the rates for screening and treatment had increased by 21% and
15% for Cohort 1, and by 41% and 15% for Cohort 2. CON-
CLUSION: While slow progress has been made in the clinical
management of fracture since the implementation of the HEDIS
osteoporosis measure, there is still an opportunity for signiﬁcant
improvement.
OSTEOPOROSIS—Methods and Concepts
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OBJECTIVES: After the recommended two-month treatment
course of risedronate for the treatment of Paget’s disease,
patients should be followed to assess the need for re-treatment.
We examined real-world treatment patterns and resource uti-
lization in patients treated with risedronate for Paget’s disease.
METHODS: Patients enrolled in a nationally representative,
multi-managed care plan claims database (1998–2004; Phar-
Metrics) with a diagnosis of Paget’s disease (>1 ICD-9 code), >1
risedronate prescription at the Paget’s dose (30mg; daily dosing),
no osteoporosis, and >1 year of follow-up after initial rise-
dronate therapy were identiﬁed. For this cohort, we evaluated:
1) Proportion of patients with risedronate use >1 month after
the recommended treatment regimen in the approved label (i.e.,
additional use); 2) Proportion of patients without risedronate
prescription (i.e., gap) from days 61 to 180, followed by use after
